MET Amplification Leads to Gefitinib Resistance in Lung Cancer by Activating ERBB3 Signaling
The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
The epidermal growth factor receptor (EGFR) kinase inhibitors gefitinib and erlotinib are effective treatments for lung cancers with EGFR activating mutations, but these tumors invariably develop drug resistance. Here, we describe a gefitinib-sensitive lung cancer cell line that developed resistance to gefitinib as a result of focal amplification of the MET proto-oncogene. inhibition of MET signaling in these cells restored their sensitivity to gefitinib. MET amplification was detected in 4 of 18 (22%) lung cancer specimens that had developed resistance to gefitinib or erlotinib. We find that amplification of MET causes gefitinib resistance by driving ERBB3 (HER3)-dependent activation of PI3K, a pathway thought to be specific to EGFR/ERBB family receptors. Thus, we propose that MET amplification may promote drug resistance in other ERBB-driven cancers as well.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Insulin-like growth factor 1 (IGF1)/IGF2, HGF/MET and HER2/HER3 have been reported to activate the PI3K/AKT and RAS/RAF/MEK/ERK axis independently of EGFR [172,173].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [173]
In the citing paper
“The proto-oncogene MET, which enforces hepatocyte growth factor receptor (HGFR, also known as MET tyrosine kinase receptor), shares several downstream pathways with EGFR, including RAS/RAF/MAPK and PI3K/AKT signaling pathways [173,183].”
From Drug Resistance in Colorectal Cancer: From Mechanism to Clinic (2022) · cites this paper as [173]
In the citing paper
“MET activation, by either gene amplification or ligand stimulation, accounts for 5–10% of lung cancer resistance to EGFR TKIs [12,14].”
From Emerging Insights into Targeted Therapy-Tolerant Persister Cells in Cancer (2021) · cites this paper as [14]
In the citing paper
“MET amplification has been reported as a mechanism of resistance to gefitinib[8] and osimertinib[23]. In our cohort, it was identified in T790M-preserved (5/19) and T790M-loss (1/21) cases, and the second most common resistance mechanism after EGFR tertiary mutations (5/42, 14%).”
From Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC (2018) · cites this paper as [8]
In the citing paper
“MET amplification has been reported as a mechanism of resistance to gefitinib[8] and osimertinib[23].”
From Landscape of EGFR-Dependent and -Independent Resistance Mechanisms to Osimertinib and Continuation Therapy Beyond Progression in EGFR -Mutant NSCLC (2018) · cites this paper as [8]
6 more claims about this paper
Create a free account to see every claim other papers make about this one.
Citations
Cites
Lynch, T. J., Bell, D. W., Sordella, R., Gurubhagavatula, S., Okimoto, R. A., Brannigan, B. W., Harris, P. L., Haserlat, S. M., Supko, J. G., Haluska, F. G., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040938 · Cited by 11,486
EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy
Paez, J. G., Jänne, P. A., Lee, J. C., Tracy, S., Greulich, H., Gabriel, S., Herman, P., Kaye, F. J., Lindeman, N., Boggon, T. J., et al. (2004) · Science · doi:10.1126/science.1099314 · Cited by 9,368
Self-citationEfficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors
Demetri, G. D., von Mehren, M., Blanke, C. D., Van den Abbeele, A. D., Eisenberg, B., Roberts, P. J., Heinrich, M. C., Tuveson, D. A., Singer, S., Janicek, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020461 · Cited by 4,389
Druker, B. J., Sawyers, C. L., Kantarjian, H., Resta, D. J., Reese, S. F., Ford, J. M., Capdeville, R., & Talpaz, M. (2001) · New England Journal of Medicine · doi:10.1056/nejm200104053441402 · Cited by 2,713
Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer
Kosaka, T., Yatabe, Y., Endoh, H., Kuwano, H., Takahashi, T., & Mitsudomi, T. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2818 · Cited by 1,228
Self-citationEscape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3
Sergina, N. V., Rausch, M., Wang, D., Blair, J., Hann, B., Shokat, K. M., & Moasser, M. M. (2007) · Nature · doi:10.1038/nature05474 · Cited by 991
Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy
Hochhaus, A., Kreil, S., Corbin, A., La Rosée, P., Müller, M., Lahaye, T., Hanfstein, B., Schoch, C., Cross, N., Berger, U., et al. (2002) · Leukemia · doi:10.1038/sj.leu.2402741 · Cited by 906
Balak, M. N., Gong, Y., Riely, G. J., Somwar, R., Li, A. R., Zakowski, M. F., Chiang, A., Yang, G., Ouerfelli, O., Kris, M. G., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1570 · Cited by 824
Molecular Correlates of Imatinib Resistance in Gastrointestinal Stromal Tumors
Heinrich, M. C., Corless, C. L., Blanke, C. D., Demetri, G. D., Joensuu, H., Roberts, P. J., Eisenberg, B. L., von Mehren, M., Fletcher, C. D. M., Sandau, K., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.2265 · Cited by 814
Yakes, F. M., Chinratanalab, W., Ritter, C. A., King, W., SEELIG, S. A., & Arteaga, C. L. (2002) · PubMed · Cited by 705
Research works printed but not linked: 2
- J. G. Christensen et al., Cancer Res.63, 7345 (2003).
- F. M. Yakes et al., Cancer Res.62, 4132 (2002).
Cited by
Items 601–700 of 1,038
ARAF mutations confer resistance to the RAF inhibitor belvarafenib in melanoma
Yen, I., Shanahan, F., Lee, J., Hong, Y. S., Shin, S. J., Moore, A. R., Sudhamsu, J., Chang, M. T., Bae, I., Dela Cruz, D., et al. (2021) · Nature · doi:10.1038/s41586-021-03515-1 · Cited by 138
Suda, K., Mizuuchi, H., Maehara, Y., & Mitsudomi, T. (2012) · Cancer and Metastasis Reviews · doi:10.1007/s10555-012-9391-7 · Cited by 151
Self-citationKrumbach, R., Schüler, J. B., Hofmann, M., Giesemann, T., Fiebig, H., & Beckers, T. L. (2011) · European Journal of Cancer · doi:10.1016/j.ejca.2010.12.019 · Cited by 147
Katayama, R., Sakashita, T., Yanagitani, N., Ninomiya, H., Horiike, A., Friboulet, L., Gainor, J. F., Motoi, N., Dobashi, A., Sakata, S., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2015.12.009 · Cited by 141
Self-citationRamalingam, S. S., Janne, P. A., Mok, T. S. K., O'Byrne, K. J., Boyer, M. J., von Pawel, J., Płużański, A., Shtivelband, M. I., Docampo, L. I., Bennouna, J., et al. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70452-8 · Cited by 149
Self-citationEathiraj, S., Palma, R., Volckova, E., Hirschi, M., France, D. S., Ashwell, M. A., & Chan, T. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.213801 · Cited by 161
Tumor heterogeneity in the clinic: is it a real problem?
Jankú, F. (2013) · Therapeutic Advances in Medical Oncology · doi:10.1177/1758834013517414 · Cited by 159
A gene-alteration profile of human lung cancer cell lines
Blanco, R., Iwakawa, R., Tang, M., Kohno, T., Angulo, B., Pío, R., Montuenga, L. M., Minna, J. D., Yokota, J., & Sánchez‐Céspedes, M. (2009) · Human Mutation · doi:10.1002/humu.21028 · Cited by 155
Lamberti, G., Andrini, E., Sisi, M., Rizzo, A., Parisi, C., Federico, A. D., Gelsomino, F., & Ardizzoni, A. (2020) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2020.103119 · Cited by 154
Molecular tumour boards — current and future considerations for precision oncology
Tsimberidou, A. M., Kahle, M., Vo, H. H., Baysal, M. A., Johnson, A., & Meric-Bernstam, F. (2023) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-023-00824-4 · Cited by 144
AURKB as a target in non-small cell lung cancer with acquired resistance to anti-EGFR therapy
Bertran-Alamillo, J., Cattan, V., Schoumacher, M., Codony-Servat, J., Giménez-Capitán, A., Cantero, F., Burbridge, M., Rodríguez, S., Teixidó, C., Roman, R., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-09734-5 · Cited by 138
Molecular‐targeted agents combination therapy for cancer: Developments and potentials
Li, F., Zhao, C., & Wang, L. (2013) · International Journal of Cancer · doi:10.1002/ijc.28261 · Cited by 156
25 Years of Small Molecular Weight Kinase Inhibitors: Potentials and Limitations
Fabbro, D. (2014) · Molecular Pharmacology · doi:10.1124/mol.114.095489 · Cited by 152
Molecularly Targeted Therapies in Non–Small-Cell Lung Cancer Annual Update 2014
Morgensztern, D., Campo, M. J., Dahlberg, S. E., Doebele, R. C., Garon, E. B., Gerber, D. E., Goldberg, S. B., Hammerman, P. S., Heist, R. S., Hensing, T. A., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000405 · Cited by 150
Remón, J., Morán, T., Majem, M., Reguart, N., Dalmau, E., Márquez-Medina, D., & LIANES, P. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2013.06.002 · Cited by 142
Targeting EGFR signalling in chronic lung disease: therapeutic challenges and opportunities
Vallath, S., Hynds, R. E., Succony, L., Janes, S. M., & Giangreco, A. (2014) · European Respiratory Journal · doi:10.1183/09031936.00146413 · Cited by 155
c-Met as a Target for Personalized Therapy
Garajová, I., Giovannetti, E., Biasco, G., & Peters, G. J. (2015) · Translational Oncogenomics · doi:10.4137/tog.s30534 · Cited by 158
Pharmacokinetic Considerations for Antibody Drug Conjugates
Lin, K., & Tibbitts, J. (2012) · Pharmaceutical Research · doi:10.1007/s11095-012-0800-y · Cited by 144
Tiedt, R., Degenkolbe, E., Furet, P., Appleton, B. A., Wagner, S., Schoepfer, J. G., Buck, E., Ruddy, D. A., Monahan, J. E., Jones, M. D., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-4433 · Cited by 139
Koeppen, H., Yu, W., Zha, J., Pandita, A., Penuel, E., Rangell, L., Raja, R., Mohan, S., Patel, R., Desai, R., et al. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1836 · Cited by 136
Trowe, T., Boukouvala, S., Calkins, K., Cutler, R. E., Fong, R., Funke, R., Gendreau, S. B., Kim, Y. D., Miller, N., Woolfrey, J. R., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4367 · Cited by 134
Targeting the c-MET signaling pathway for cancer therapy
Liu, X., Yao, W., Newton, R. C., & Scherle, P. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.7.997 · Cited by 143
Showering c-MET-dependent cancers with drugs
Knudsen, B. S., & Woude, G. V. (2008) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2008.02.001 · Cited by 137
How Cancer Shapes Evolution and How Evolution Shapes Cancer
Casás-Selves, M., & DeGregori, J. (2011) · Evolution: Education and Outreach · doi:10.1007/s12052-011-0373-y · Cited by 134
Lee, J., Lee, Y.-M., Chang, G., Yu, S., Hsieh, W.-Y., Chen, J. J. W., Chen, H., & Yang, P. (2011) · PLoS ONE · doi:10.1371/journal.pone.0023756 · Cited by 142
Mutations and Response to Epidermal Growth Factor Receptor Inhibitors
Laurent-Puig, P., Lievre, A., & Blons, H. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0905 · Cited by 133
Buchanan, S. G., Hendle, J., Lee, P. S., Smith, C. R., Bounaud, P., Jessen, K., Tang, C. M., Huser, N. H., Felce, J. D., Froning, K., et al. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0477 · Cited by 150
Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer
Le, X., Antony, R., Razavi, P., Treacy, D. J., Luo, F., Ghandi, M., Castel, P., Scaltriti, M., Baselga, J., & Garraway, L. A. (2016) · Cancer Discovery · doi:10.1158/2159-8290.cd-16-0305 · Cited by 132
Use of Fluorescence In Situ Hybridization (FISH) in Diagnosis and Tailored Therapies in Solid Tumors
Olszewska, N., Kowalewski, J., & Lewandowska, M. A. (2020) · Molecules · doi:10.3390/molecules25081864 · Cited by 155
Corcoran, R. B., Settleman, J., & Engelman, J. A. (2011) · Oncotarget · doi:10.18632/oncotarget.262 · Cited by 131
Self-citationA survey of glioblastoma genomic amplifications and deletions
Rao, S. K., Edwards, J. B., Joshi, A. D., Siu, I., & Riggins, G. J. (2009) · Journal of Neuro-Oncology · doi:10.1007/s11060-009-9959-4 · Cited by 132
Neal, J. W., Dahlberg, S. E., Wakelee, H. A., Aisner, S. C., Bowden, M., Huang, Y., Carbone, D. P., Gerstner, G. J., Lerner, R. E., Rubin, J. L., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30561-7 · Cited by 144
Novel Therapeutic Targets in Non-small Cell Lung Cancer
Jankú, F., Garrido‐Laguna, I., Petruzelka, L. B., Stewart, D. J., & Kurzrock, R. (2011) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31822944b3 · Cited by 139
Cheung, H. W., Du, J., Boehm, J. S., He, F., Weir, B. A., Wang, X., Butaney, M., Sequist, L. V., Luo, B., Engelman, J. A., et al. (2011) · Cancer Discovery · doi:10.1158/2159-8290.cd-11-0046 · Cited by 130
Self-citationTankyrase and the Canonical Wnt Pathway Protect Lung Cancer Cells from EGFR Inhibition
Casás-Selves, M., Kim, J., Zhang, Z., Helfrich, B. A., Gao, D., Porter, C. C., Scarborough, H. A., Bunn, P. A., Chan, D. C., Tan, A. C., et al. (2012) · Cancer Research · doi:10.1158/0008-5472.can-11-2848 · Cited by 130
Firtina Karagonlar, Z., Koc, D., Iscan, E., Erdal, E., & Atabey, N. (2016) · Cancer Science · doi:10.1111/cas.12891 · Cited by 131
Mueller, K. L., Hunter, L. A., Ethier, S. P., & Boerner, J. L. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0132 · Cited by 130
Resistance to ROS1 Inhibition Mediated by EGFR Pathway Activation in Non-Small Cell Lung Cancer
Davies, K. D., Mahale, S., Astling, D. P., Aisner, D. L., Le, A. T., Hinz, T. K., Vaishnavi, A., Bunn, P. A., Heasley, L. E., Tan, A.-C., et al. (2013) · PLoS ONE · doi:10.1371/journal.pone.0082236 · Cited by 130
Decorin Antagonizes Met Receptor Activity and Down-regulates β-Catenin and Myc Levels
Buraschi, S., Pal, N., Tyler-Rubinstein, N., Owens, R. T., Neill, T., & Iozzo, R. V. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.172841 · Cited by 145
Togashi, Y., Masago, K., Fukudo, M., Terada, T., Fujita, S., Irisa, K., Sakamori, Y., Kim, Y. H., Mio, T., Inui, K., et al. (2010) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e3181e2138b · Cited by 133
Johnson, M. L., Yu, H. A., Hart, E. M., Weitner, B. B., Rademaker, A. W., Patel, J. D., Kris, M. G., & Riely, G. J. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7328 · Cited by 130
EGFR-mutated oncogene-addicted non-small cell lung cancer: Current trends and future prospects
Soria, J., Mok, T. S. K., Cappuzzo, F., & Janne, P. A. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.10.003 · Cited by 141
Self-citationFibroblast growth factor receptors, developmental corruption and malignant disease
Kelleher, F. C., O’Sullivan, H., Smyth, E. C., McDermott, R., & Viterbo, A. (2013) · Carcinogenesis · doi:10.1093/carcin/bgt254 · Cited by 140
Johnson, G. L., Stuhlmiller, T. J., Angus, S. P., Zawistowski, J. S., & Graves, L. M. (2014) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-13-1081 · Cited by 129
Targeting Cancer with Small-Molecular-Weight Kinase Inhibitors
Fabbro, D., Cowan-Jacob, S. W., Möbitz, H., & Martiny-Baron, G. (2012) · Methods in Molecular Biology · doi:10.1007/978-1-61779-337-0_1 · Cited by 127
Zhang, X., Liu, G., Kang, Y., Dong, Z., Qian, Q., & Ma, X. (2013) · PLoS ONE · doi:10.1371/journal.pone.0057692 · Cited by 129
McDermott, U., & Settleman, J. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.22.9054 · Cited by 129
Lee, J. J.-K., Shin, J. Y., Kim, S., Lee, S., Park, C. C., Kim, J. Y., Koh, Y., Keam, B., Min, H. S., Kim, T. M., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt127 · Cited by 137
Liu, X., Lu, X., Zhen, F., Jin, S., Yu, T., Zhu, Q., Wang, W. T., Xu, K., Yao, J., & Guo, R. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.02.010 · Cited by 135
Molecular cancer therapy: Can our expectation be MET?
Migliore, C., & Giordano, S. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.01.022 · Cited by 128
MET: A Critical Player in Tumorigenesis and Therapeutic Target
Graveel, C. R., Tolbert, D., & Vande Woude, G. F. (2013) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a009209 · Cited by 128
“Approximately 50% of the tumors develop resistance owing to a secondary mutation in EGFR; however, focal amplification of MET was observed in 22% of the resistant tumors (Engelman et al. 2007).”
BackgroundKosaka, T., Yamaki, E., Mogi, A., & Kuwano, H. (2011) · BioMed Research International · doi:10.1155/2011/165214 · Cited by 146
Self-citationDual Roles of the Transcription Factor Grainyhead-like 2 (GRHL2) in Breast Cancer
Werner, S., Frey, S., Riethdorf, S., Schulze, C., Alawi, M., Kling, L., Vafaizadeh, V., Sauter, G., Terracciano, L., Schumacher, U., et al. (2013) · Journal of Biological Chemistry · doi:10.1074/jbc.m113.456293 · Cited by 128
Robinson, M. K., Hodge, K. M., Horak, E., Sundberg, Å. L., Russeva, M., Shaller, C. C., von Mehren, M., Shchaveleva, I., Simmons, H. H., Marks, J. D., et al. (2008) · British Journal of Cancer · doi:10.1038/sj.bjc.6604700 · Cited by 128
Minuti, G., Cappuzzo, F., Duchnowska, R., Jassem, J., Fabi, A., O’Brien, T., Mendoza, A. D., Landi, L., Biernat, W., Czartoryska-Arłukowicz, B., et al. (2012) · British Journal of Cancer · doi:10.1038/bjc.2012.335 · Cited by 127
Self-citationFreudenberg, J. A., Wang, Q., Katsumata, M., Drebin, J. A., Nagatomo, I., & Greene, M. I. (2009) · Experimental and Molecular Pathology · doi:10.1016/j.yexmp.2009.05.001 · Cited by 149
Lu, R., Chang, Y., Chen, M., & Wu, H. (2011) · Biomaterials · doi:10.1016/j.biomaterials.2010.12.061 · Cited by 129
Singh, D. K., Ku, C., Wichaidit, C., Steininger, R. J., Wu, L. F., & Altschuler, S. J. (2010) · Molecular Systems Biology · doi:10.1038/msb.2010.22 · Cited by 127
Bachleitner‐Hofmann, T., Sun, M. Y., Chen, C., Tang, L. H., Song, L., Zeng, Z., Shah, M. A., Christensen, J. G., Rosen, N. X., Solit, D. B., et al. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0374 · Cited by 136
Self-citationvan der Stegen, S. J. C., Davies, D. M., Wilkie, S., Foster, J., Sosabowski, J. K., Burnet, J., Whilding, L. M., Petrovic, R. M., Ghaem-Maghami, S., Mather, S., et al. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1301523 · Cited by 126
Scagliotti, G. V., Novello, S., Schiller, J. H., Hirsh, V., Sequist, L. V. D., Soria, J., von Pawel, J., Schwartz, B. E., von Roemeling, R., & Sandler, A. B. (2012) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.01.003 · Cited by 129
Breindel, J. L., Haskins, J. W., Cowell, E. P., Zhao, M., Nguyen, D. X., & Stern, D. F. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-3775 · Cited by 140
Yi, H. G., Kim, H. J., Kim, Y. J., Han, S., Oh, D., Lee, S., Kim, D., Im, S., Kim, T., Kim, C. S., et al. (2008) · Lung Cancer · doi:10.1016/j.lungcan.2008.10.016 · Cited by 128
Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors
Karamouzis, M. V., Konstantinopoulos, P. A., & Papavassiliou, A. G. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70137-8 · Cited by 131
Costa, D. B., Schumer, S., Tenen, D. G., & Kobayashi, S. S. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.9039 · Cited by 143
Reungwetwattana, T., Weroha, S. J., & Molina, J. R. (2011) · Clinical Lung Cancer · doi:10.1016/j.cllc.2011.09.004 · Cited by 136
Jung, S. K., Lee, M., Lim, D. Y., Kim, J., Singh, P., Lee, S., Jeong, C., Lim, T., Chen, H., Chi, Y., et al. (2014) · Journal of Biological Chemistry · doi:10.1074/jbc.m114.585513 · Cited by 125
Self-citationUnderstanding the biology of HER3 receptor as a therapeutic target in human cancer
Lyu, H., Han, A., Polsdofer, E., Liu, S., & Liu, B. (2018) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2018.05.010 · Cited by 136
Hensing, T. A., Chawla, A., Batra, R., & Salgia, R. (2013) · Advances in experimental medicine and biology · doi:10.1007/978-1-4614-8778-4_5 · Cited by 141
Clinical implications of molecular heterogeneity in triple negative breast cancer
Lehmann, B. D., & Pietenpol, J. A. (2015) · The Breast · doi:10.1016/j.breast.2015.07.009 · Cited by 135
Fighting cancer drug resistance: Opportunities and challenges for mutation-specific EGFR inhibitors
Juchum, M., Günther, M., & Laufer, S. (2015) · Drug Resistance Updates · doi:10.1016/j.drup.2015.05.002 · Cited by 134
Yoshida, T., Ishii, G., Goto, K., Neri, S., Hashimoto, H., Yoh, K., Niho, S., Umemura, S., Matsumoto, S., Ohmatsu, H., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-0846 · Cited by 123
An eight-miRNA signature as a potential biomarker for predicting survival in lung adenocarcinoma
Li, X., Shi, Y., Yin, Z., Xue, X., & Zhou, B. (2014) · Journal of Translational Medicine · doi:10.1186/1479-5876-12-159 · Cited by 134
Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers
Cortot, A. B., Kherrouche, Z., Descarpentries, C., Wislez, M., Baldacci, S., Furlan, A., & Tulasne, D. (2016) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djw262 · Cited by 135
Exploiting evolutionary steering to induce collateral drug sensitivity in cancer
Acar, A., Nichol, D., Fernández-Mateos, J., Cresswell, G. D., Barozzi, I., Hong, S. P., Trahearn, N., Spiteri, I., Stubbs, M., Burke, R., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15596-z · Cited by 150
Cheng, Y., Zhang, T., & Xu, Q. (2021) · MedComm · doi:10.1002/mco2.105 · Cited by 142
Drug resistance in lung cancer
Ramesh, R. (2010) · Lung Cancer Targets and Therapy · doi:10.2147/lctt.s6861 · Cited by 142
Garner, A. P., Bialucha, C. U., Sprague, E. R., Garrett, J. T., Sheng, Q., Li, S., Sineshchekova, O., Saxena, P., Sutton, C. R., Chen, D., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-13-1198 · Cited by 129
Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data
Jorge, S. E., Kobayashi, S. S., & Costa, D. B. (2014) · Brazilian Journal of Medical and Biological Research · doi:10.1590/1414-431x20144099 · Cited by 131
How Genetically Engineered Mouse Tumor Models Provide Insights Into Human Cancers
Politi, K., & Pao, W. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.30.8304 · Cited by 123
EPHA2 Blockade Overcomes Acquired Resistance to EGFR Kinase Inhibitors in Lung Cancer
Amato, K. R., Wang, S., Tan, L., Hastings, A. K., Song, W., Lovly, C. M., Meador, C. B., Ye, F., Lu, P., Balko, J. M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-15-0717 · Cited by 123
Suzawa, K., Offin, M., Lu, D., Kurzatkowski, C., Vojnic, M., Smith, R. S., Sabari, J. K., Tai, H., Mattar, M., Khodos, I., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1640 · Cited by 121
Targeting the Complement Pathway as a Therapeutic Strategy in Lung Cancer
Kleczko, E. K., Kwak, J., Schenk, E. L., & Nemenoff, R. A. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.00954 · Cited by 133
Scharpenseel, H., Hanssen, A., Loges, S., Mohme, M., Bernreuther, C., Peine, S., Lamszus, K., Goy, Y., Petersen, C., Westphal, M., et al. (2019) · Scientific Reports · doi:10.1038/s41598-019-43678-6 · Cited by 124
Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers
Misale, S., Bozic, I., Tong, J., Peraza-Penton, A., Lallo, A., Baldi, F., Lin, K. H., Truini, M., Trusolino, L., Bertotti, A., et al. (2015) · Nature Communications · doi:10.1038/ncomms9305 · Cited by 122
Della Corte, C. M., Bellevicine, C., Vicidomini, G., Vitagliano, D., Malapelle, U., Accardo, M., Fabozzi, A., Fiorelli, A., Fasano, M., Papaccio, F., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-14-3319 · Cited by 122
“As MET has been demonstrated to interact with HER3 to mediate resistance to EGFR inhibitors (25), we explored the expression of HER3 in SMO immunoprecipitates.”
BackgroundTherapeutic target database update 2014: a resource for targeted therapeutics
Qin, C., Zhang, C., Zhu, F., Xu, F., Chen, S. Y., Zhang, P., Li, Y. H., Yang, S. Y., Wei, Y. Q., Tao, L., et al. (2014) · Nucleic Acids Research · doi:10.1093/nar/gkt1129 · Cited by 121
Tanizaki, J., Okamoto, I., Sakai, K., & Nakagawa, K. (2011) · British Journal of Cancer · doi:10.1038/bjc.2011.322 · Cited by 123
Acquired resistance to drugs targeting receptor tyrosine kinases
Rosenzweig, S. A. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.12.025 · Cited by 129
Murakami, A., Takahashi, F., Nurwidya, F., Kobayashi, I., Minakata, K., Hashimoto, M., Nara, T., Kato, M., Tajima, K., Shimada, N., et al. (2014) · PLoS ONE · doi:10.1371/journal.pone.0086459 · Cited by 122
Liang, H., & Wang, M. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s231257 · Cited by 141
Xu, H., Stabile, L. P., Gubish, C. T., Gooding, W. E., Grandis, J. R., & Siegfried, J. M. (2011) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-3339 · Cited by 131
Buettner, R., Wolf, J., & Thomas, R. K. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.45.9867 · Cited by 121
Oddo, D., Sennott, E. M., Barault, L., Valtorta, E., Arena, S., Cassingena, A., Filiciotto, G., Marzolla, G., Elez, E., van Geel, R. M. J. M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-0396 · Cited by 121
Self-citationYAP and TAZ in Lung Cancer: Oncogenic Role and Clinical Targeting
Sardo, F. L., Strano, S., & Blandino, G. (2018) · Cancers · doi:10.3390/cancers10050137 · Cited by 128
Looyenga, B. D., Hutchings, D., Cherni, I., Kingsley, C., Weiss, G. J., & MacKeigan, J. P. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030820 · Cited by 120
DNA amplification is a ubiquitous mechanism of oncogene activation in lung and other cancers
Lockwood, W. W., Chari, R., Coe, B. P., Girard, L., MacAulay, C. E., Lam, S. C., Gazdar, A. F., Minna, J. D., & Lam, W. L. (2008) · Oncogene · doi:10.1038/onc.2008.98 · Cited by 120
Afatinib: emerging next-generation tyrosine kinase inhibitor for NSCLC
Agulnik, M., Nelson, Ziehr, & Johnson, J. R. (2013) · OncoTargets and Therapy · doi:10.2147/ott.s23165 · Cited by 134
MET as a target for treatment of chest tumors
Cipriani, N. A., Abidoye, O. O., Vokes, E., & Salgia, R. (2009) · Lung Cancer · doi:10.1016/j.lungcan.2008.06.011 · Cited by 120
Li, Q.-H., Wang, Y.-Z., Tu, J., Liu, C.-W., Yuan, Y.-J., Lin, R., He, W.-L., Cai, S.-R., He, Y.-L., & Ye, J.-N. (2020) · Gastroenterology Report · doi:10.1093/gastro/goaa026 · Cited by 119
“transcription 3 (STAT3) [124]; besides, HGFR can also be coupled with HER3 to form a heterodimer under certain conditions [125].”
Background
Metadata
- Authors
- Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., Lindeman, N., Gale, C.-M., Zhao, X., Christensen, J., Kosaka, T., Holmes, A. J., Rogers, A. M., Cappuzzo, F., Mok, T., Lee, C., Johnson, B. E., Cantley, L. C., & Jänne, P. A.
- Affiliations
- Beth Israel Deaconess Medical Center (US)
- Brigham and Women's Hospital (US)
- Massachusetts General Hospital Cancer Center, Boston, MA 02114, USA.
- ORCID
- Venue
- Science
- Published
- 2007-05-18
- Volume
- 316
- Issue
- 5827
- Pages
- 1039-1043
- ISSN
- 0036-8075 (ISSN-L)
- 1095-9203
- OpenAlex
- W1998971866
- Cited by
- 4,496
- References
- 22
- Citations by year
- 2026: 97 · 2025: 109 · 2024: 123 · 2023: 136 · 2022: 152 · 2021: 191 · 2020: 182 · 2019: 214 · 2018: 269 · 2017: 288 · 2016: 291 · 2015: 375 · 2014: 349 · 2013: 369 · 2012: 345
- FWCI
- 207.87
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Science (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5r01ca111560-05)
- National Cancer Institute (R01-CA111560, P01CA089021, R01CA114465, P20CA090578, P20 CA 90578-02, 1K12CA87723-01, K08CA120060, K12CA087723)
- National Institute of General Medical Sciences (GM 41890, R01GM041890)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
- Health Sciences › Medicine › Oncology › HER2/EGFR in Cancer Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Genomics and Diagnostics
- Keywords
- MET amplification, gefitinib resistance, lung cancer, HER3, PI3K signaling, EGFR kinase inhibitors, erlotinib, drug resistance, ErbB receptors, MET oncogene
- MeSH terms
- Gefitinib, Proto-Oncogene Mas, Animals, Antineoplastic Agents, Carcinoma, Non-Small-Cell Lung, Cricetulus, Enzyme Inhibitors, Gene Amplification, Cricetinae, Humans, Indoles, Lung Neoplasms, Phosphorylation, Proto-Oncogene Proteins, Quinazolines, Sulfones, Signal Transduction, CHO Cells, Receptors, Growth Factor, Drug Resistance, Neoplasm, Proto-Oncogene Proteins c-met, Phosphatidylinositol 3-Kinases, Receptor, ErbB-3, Cell Line, Tumor, Cell Proliferation, Proto-Oncogene Proteins c-akt
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.